Cargando…

Case Report: Keratoacanthoma and type I diabetes secondary to treatment with PM8001, a bifunctional fusion protein targeting TGF-β and PD-L1

Immune-related adverse reactions primarily involve the skin and the endocrine, digestive, and respiratory systems. In the endocrine system, these adverse effects mainly include hypophysitis, thyroiditis, hypoadrenalism, and rarely, diabetes mellitus. The most common symptoms in the skin are pruritus...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Rongbin, Xu, Hailing, Fu, Xinyu, Yu, Yingying, Lv, Dongqing, Li, Yujing, He, Susu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430778/
https://www.ncbi.nlm.nih.gov/pubmed/37593095
http://dx.doi.org/10.3389/fonc.2023.1046266
_version_ 1785091044584456192
author Qi, Rongbin
Xu, Hailing
Fu, Xinyu
Yu, Yingying
Lv, Dongqing
Li, Yujing
He, Susu
author_facet Qi, Rongbin
Xu, Hailing
Fu, Xinyu
Yu, Yingying
Lv, Dongqing
Li, Yujing
He, Susu
author_sort Qi, Rongbin
collection PubMed
description Immune-related adverse reactions primarily involve the skin and the endocrine, digestive, and respiratory systems. In the endocrine system, these adverse effects mainly include hypophysitis, thyroiditis, hypoadrenalism, and rarely, diabetes mellitus. The most common symptoms in the skin are pruritus, rash, and infrequently, eruptive keratoacanthoma. Here, we report a case of a 67-year-old woman who developed eruptive keratoacanthoma of the skin 6 weeks after beginning treatment with a bispecific antibody (PM8001), targeting both programmed cell death receptor 1 and transforming growth factor β, as well as type I diabetes mellitus–induced ketoacidosis after 13 weeks. The type I diabetes appeared to stabilize after insulin treatment, and the keratoacanthoma gradually resolved after drug discontinuation. This case report describes a case of the effects of PM8001 immunotherapy on the endocrine glands and skin, together with a review of the relevant literature, and summarizes the different clinical characteristics of rare immune-related adverse events resulting from PM8001 immunotherapy to provide a reference for their early detection, diagnosis, and treatment.
format Online
Article
Text
id pubmed-10430778
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104307782023-08-17 Case Report: Keratoacanthoma and type I diabetes secondary to treatment with PM8001, a bifunctional fusion protein targeting TGF-β and PD-L1 Qi, Rongbin Xu, Hailing Fu, Xinyu Yu, Yingying Lv, Dongqing Li, Yujing He, Susu Front Oncol Oncology Immune-related adverse reactions primarily involve the skin and the endocrine, digestive, and respiratory systems. In the endocrine system, these adverse effects mainly include hypophysitis, thyroiditis, hypoadrenalism, and rarely, diabetes mellitus. The most common symptoms in the skin are pruritus, rash, and infrequently, eruptive keratoacanthoma. Here, we report a case of a 67-year-old woman who developed eruptive keratoacanthoma of the skin 6 weeks after beginning treatment with a bispecific antibody (PM8001), targeting both programmed cell death receptor 1 and transforming growth factor β, as well as type I diabetes mellitus–induced ketoacidosis after 13 weeks. The type I diabetes appeared to stabilize after insulin treatment, and the keratoacanthoma gradually resolved after drug discontinuation. This case report describes a case of the effects of PM8001 immunotherapy on the endocrine glands and skin, together with a review of the relevant literature, and summarizes the different clinical characteristics of rare immune-related adverse events resulting from PM8001 immunotherapy to provide a reference for their early detection, diagnosis, and treatment. Frontiers Media S.A. 2023-08-01 /pmc/articles/PMC10430778/ /pubmed/37593095 http://dx.doi.org/10.3389/fonc.2023.1046266 Text en Copyright © 2023 Qi, Xu, Fu, Yu, Lv, Li and He https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Qi, Rongbin
Xu, Hailing
Fu, Xinyu
Yu, Yingying
Lv, Dongqing
Li, Yujing
He, Susu
Case Report: Keratoacanthoma and type I diabetes secondary to treatment with PM8001, a bifunctional fusion protein targeting TGF-β and PD-L1
title Case Report: Keratoacanthoma and type I diabetes secondary to treatment with PM8001, a bifunctional fusion protein targeting TGF-β and PD-L1
title_full Case Report: Keratoacanthoma and type I diabetes secondary to treatment with PM8001, a bifunctional fusion protein targeting TGF-β and PD-L1
title_fullStr Case Report: Keratoacanthoma and type I diabetes secondary to treatment with PM8001, a bifunctional fusion protein targeting TGF-β and PD-L1
title_full_unstemmed Case Report: Keratoacanthoma and type I diabetes secondary to treatment with PM8001, a bifunctional fusion protein targeting TGF-β and PD-L1
title_short Case Report: Keratoacanthoma and type I diabetes secondary to treatment with PM8001, a bifunctional fusion protein targeting TGF-β and PD-L1
title_sort case report: keratoacanthoma and type i diabetes secondary to treatment with pm8001, a bifunctional fusion protein targeting tgf-β and pd-l1
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430778/
https://www.ncbi.nlm.nih.gov/pubmed/37593095
http://dx.doi.org/10.3389/fonc.2023.1046266
work_keys_str_mv AT qirongbin casereportkeratoacanthomaandtypeidiabetessecondarytotreatmentwithpm8001abifunctionalfusionproteintargetingtgfbandpdl1
AT xuhailing casereportkeratoacanthomaandtypeidiabetessecondarytotreatmentwithpm8001abifunctionalfusionproteintargetingtgfbandpdl1
AT fuxinyu casereportkeratoacanthomaandtypeidiabetessecondarytotreatmentwithpm8001abifunctionalfusionproteintargetingtgfbandpdl1
AT yuyingying casereportkeratoacanthomaandtypeidiabetessecondarytotreatmentwithpm8001abifunctionalfusionproteintargetingtgfbandpdl1
AT lvdongqing casereportkeratoacanthomaandtypeidiabetessecondarytotreatmentwithpm8001abifunctionalfusionproteintargetingtgfbandpdl1
AT liyujing casereportkeratoacanthomaandtypeidiabetessecondarytotreatmentwithpm8001abifunctionalfusionproteintargetingtgfbandpdl1
AT hesusu casereportkeratoacanthomaandtypeidiabetessecondarytotreatmentwithpm8001abifunctionalfusionproteintargetingtgfbandpdl1